Article
Oncology
Sheehyun Kim, Yoojoo Lim, Jun-Kyu Kang, Hwang-Phill Kim, Hanseong Roh, Su Yeon Kim, Dongin Lee, Duhee Bang, Seung-Yong Jeong, Kyu Joo Park, Sae-Won Han, Tae-You Kim
Summary: This study analyzed serial blood samples from metastatic colorectal cancer patients and sequenced ctDNA to evaluate its clinical utility. The results showed that ctDNA clearance after chemotherapy was associated with longer progression-free survival, independent of radiological response. Longitudinal ctDNA monitoring detected ctDNA progression earlier than radiological progressive disease in a significant percentage of patients.
BRITISH JOURNAL OF CANCER
(2022)
Article
Medicine, General & Internal
Andrew A. Davis, Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Whitney L. Hensing, Leslie Bucheit, Ami N. Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S. Dai, Elyssa N. Denault, Nusayba A. Bagegni, Mateusz Opyrchal, Foluso O. Ademuyiwa, Ron Bose, William J. Gradishar, Amir Behdad, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli
Summary: This study analyzed genomic differences in circulating tumor DNA (ctDNA) among patients with invasive lobular carcinoma (ILC), invasive ductal carcinoma (IDC), and mixed histology. The results showed that ILC was associated with specific HR+ HER2 negative and HER2 low characteristics. Higher levels of single nucleotide variations (SNVs) were observed in ILC patients compared to IDC or mixed histology patients. Mutations in CDFII, ERBB2, and PTEN genes were significantly associated with HR+ HER2 negative ILC. Additionally, mutations in the PI3K pathway genes were more common in ILC patients. These findings have implications for histologic classification and precision medicine treatment.
Article
Medicine, Research & Experimental
Hao Liao, Jiayang Zhang, Tiantian Zheng, Xiaoran Liu, Jianxin Zhong, Bin Shao, Xiaoxi Dong, Xiaohong Wang, Pan Du, Bonnie L. King, Shidong Jia, Jianjun Yu, Huiping Li
Summary: This study revealed the molecular profiles of Chinese patients with advanced breast cancer (ABC) and highlighted the clinical importance of ctDNA-derived markers for predicting treatment response, prognosis, and disease progression. Common gene mutations included TP53 and PIK3CA, while frequent CNVs included amplifications of ERBB2 and FGFR1. Furthermore, TP53 and PIK3CA mutations were associated with survival outcomes in triple-negative breast cancer (TNBC) patients, and high ctDNA fraction and blood-based tumor mutation burden (bTMB) were associated with progression-free survival (PFS) in TNBC and HER2+ patients.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Axel Muendlein, Kathrin Geiger, Stella Gaenger, Tobias Dechow, Christoph Nonnenbroich, Andreas Leiherer, Heinz Drexel, Andreas Gaumann, Wolfgang Jagla, Thomas Winder, Frank Mayer, Thomas Decker
Summary: Mutational analysis of circulating tumor DNA shows promise in predicting the prognosis of metastatic breast cancer, with the number of mutations correlating with progression free survival and overall survival. Mutational status of ESR1 and TP53 can serve as predictive markers for patient outcomes in advanced breast cancer management.
SCIENTIFIC REPORTS
(2021)
Article
Dermatology
Soichiro Sawamura, Tselmeg Mijiddorj Myangat, Ikko Kajihara, Kenichiro Tanaka, Maho Ide, Ryoko Sakamoto, Saki Otsuka-Maeda, Hisashi Kanemaru, Yuki Nishimura, Saori Kanazawa-Yamada, Kayo Kashiwada-Nakamura, Noritoshi Honda, Katsunari Makino, Jun Aoi, Toshikatsu Igata, Takamitsu Makino, Sinichi Masuguchi, Satoshi Fukushima, Hironobu Ihn
Summary: The study investigated genomic alterations in cfDNA and tumor tissue DNA of patients with metastatic EMPD using CAPP-Seq method, revealing mutations in some genes not previously reported and showing that variant allele frequency of some mutated genes correlated with disease progression in patients.
EXPERIMENTAL DERMATOLOGY
(2022)
Review
Oncology
Brad A. Davidson, Sarah Croessmann, Ben H. Park
Summary: Advancements in genomic strategies and targeted therapies have enabled precision medicine to revolutionize oncology. Liquid biopsy, which gathers genetic information through minimally invasive methods, offers valuable insights for potential targeted therapies and tumor surveillance. However, lack of prospective clinical trials showing direct patient benefit has hindered the widespread implementation of liquid biopsies in standard clinical applications.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Ilona Krol, Fabienne D. Schwab, Roberta Carbone, Mathilde Ritter, Sabrina Picocci, Marzia L. De Marni, Grazyna Stepien, Gian M. Franchi, Andrea Zanardi, Marco D. Rissoglio, Alfredo Covelli, Guido Guidi, Daniele Scarinci, Francesc Castro-Giner, Luca Mazzarella, Claudio Doglioni, Francesca Borghi, Paolo Milani, Christian Kurzeder, Walter P. Weber, Nicola Aceto
Summary: By utilizing nanostructured titanium oxide-coated slides for shear-free CTC identification, this study detected clustered CTCs in multiple early breast cancer patients prior to surgical treatment, indicating their presence at early stages of the disease. These results emphasize the importance of understanding metastasis biology and the potential for anti-cluster therapeutics intervention even during the early manifestation of breast cancer.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Ben M. Eyck, Maurice P. H. M. Jansen, Bo Jan Noordman, Peggy N. Atmodimedjo, Berend J. van der Wilk, John W. M. Martens, Jean A. Helmijr, Corine M. Beaufort, Bianca Mostert, Michail Doukas, Bas P. L. Wijnhoven, Sjoerd M. Lagarde, J. Jan B. van Lanschot, Winand N. M. Dinjens
Summary: Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemoradiotherapy (nCRT) can be highly indicative of major residual disease in patients with esophageal cancer. Pre-treatment and post-nCRT ctDNA detection may help identify patients at high risk of disease progression.
JOURNAL OF PATHOLOGY
(2023)
Article
Oncology
Katherine Clifton, Jingqin Luo, Yu Tao, Jennifer Saam, Thereasa Rich, Anna Roshal, Ashley Frith, Caron Rigden, Foluso Ademuyiwa, Katherine Weilbaecher, Leonel Hernandez-Aya, Lindsay L. Peterson, Nusayba Bagegni, Rama Suresh, Ron Bose, Mateusz Opyrchal, Tanya M. Wildes, Cynthia Ma
Summary: This study aimed to assess mutation profiles in older adult breast cancer patients using a ctDNA assay, and found more frequent ATM, BRAF, and PIK3CA mutations in older patients. Results also showed that ctDNA testing influenced treatment management in a portion of patients from a single institution.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Andi K. Cani, Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia-Jen Liu, Jackie Pierce, Kieran Bradbury, Elaine Kilgour, Kimberly Aung, Gaia Schiavon, Danielle Carroll, T. Hedley Carr, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Vicky Rowlands, Elizabeth A. Harrington, J. Carl Barrett, Nitharsan Sathiyayogan, Christopher Morrow, Valeria Sero, Anne C. Armstrong, Richard Baird, Erika Hamilton, Seock-Ah Im, Komal Jhaveri, Manish R. Patel, Caroline Dive, Scott A. Tomlins, Aaron M. Udager, Daniel F. Hayes, Costanza Paoletti
Summary: Research has shown that analyzing circulating tumor cells (CTC) in the blood can provide information about genomic alterations in breast cancer, potentially enabling more precise cancer treatment. By analyzing CTC, potential drug targets within patients can be identified, guiding the selection of targeted therapies, with feasible treatment opportunities discovered in 73% of patients.
MOLECULAR ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Kyoungmin Lee, Jongwon Lee, Jungmin Choi, Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, In Hae Park
Summary: We investigated the genetic alterations in heavily treated HER2+ metastatic breast cancer patients. Through targeted sequencing of ctDNA, we identified 65 pathogenic gene alterations in 99 samples. TP53 and PIK3CA mutations, as well as higher ctDNA fraction, correlated with shorter progression-free survival. HRD-related gene mutations were more frequent in ctDNA and associated with resistance to treatment. New pathogenic variants were found at the end of treatment.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Lavanya Sivapalan, Graeme J. Thorn, Emanuela Gadaleta, Hemant M. Kocher, Helen Ross-Adams, Claude Chelala
Summary: This study explores the utility of circulating tumour DNA (ctDNA) in longitudinal tumour monitoring of pancreatic ductal adenocarcinoma (PDAC). The results show that ctDNA is sensitive in monitoring disease burden and can be used to track clonal evolution and evaluate treatment response.
Review
Surgery
Ryan Cohen, Cameron F. Platell, Melanie J. McCoy, Katie Meehan, Kathy Fuller
Summary: Circulating tumour DNA analysis can be performed through tumour-informed and tumour-agnostic approaches. Preanalytical and laboratory considerations are important before proceeding with in-house testing. The detection of circulating tumour DNA after curative resection is associated with a significant risk of recurrence. Adjuvant chemotherapy for patients with stage II disease and detectable postoperative circulating tumour DNA reduces the number of patients receiving chemotherapy while providing non-inferior recurrence-free survival compared with standard histopathological decision-making algorithms. Monitoring circulating tumour DNA during post-treatment surveillance allows for earlier diagnosis of recurrence.
BRITISH JOURNAL OF SURGERY
(2023)
Review
Oncology
Joanna Kapeleris, Majid Ebrahimi Warkiani, Arutha Kulasinghe, Ian Vela, Liz Kenny, Rahul Ladwa, Kenneth O'Byrne, Chamindie Punyadeera
Summary: Despite efforts to improve early diagnosis of NSCLC, most patients still present with advanced stage disease. Liquid biopsy, as an emerging method, provides remarkable advantages in cancer diagnosis and prognosis, offering earlier monitoring and evaluation.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Rabia Rasool, Inam Ullah, Bismillah Mubeen, Sultan Alshehri, Syed Sarim Imam, Mohammed M. Ghoneim, Sami I. Alzarea, Fahad A. Al-Abbasi, Bibi Nazia Murtaza, Imran Kazmi, Muhammad Shahid Nadeem
Summary: Breast cancer is a diverse disease caused by mutations and epigenetic aberrations, and studying genomic instability is crucial for personalized treatment and the identification of prognostic markers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
N. C. Turner, C. Swift, B. Jenkins, L. Kilburn, M. Coakley, M. Beaney, L. Fox, K. Goddard, I. Garcia-Murillas, P. Proszek, P. Hall, C. Harper-Wynne, T. Hickish, S. Kernaghan, I. R. Macpherson, A. F. C. Okines, C. Palmieri, S. Perry, K. Randle, C. Snowdon, H. Stobart, A. M. Wardley, D. Wheatley, S. Waters, M. C. Winter, M. Hubank, S. D. Allen, J. M. Bliss
Summary: The c-TRAK TN study is the first prospective study to evaluate the clinical utility of ctDNA testing in guiding therapy in TNBC. It found that TNBC patients had a high rate of metastatic disease on ctDNA detection. These findings have important implications for future trial design, emphasizing the importance of starting ctDNA testing early and using more sensitive and/or frequent ctDNA testing regimes.
ANNALS OF ONCOLOGY
(2023)
Correction
Multidisciplinary Sciences
R. C. Coombes, P. D. Badman, J. P. Lozano-Kuehne, X. Liu, I. R. Macpherson, I. Zubairi, R. D. Baird, N. Rosenfeld, J. Garcia-Corbacho, N. Cresti, R. Plummer, A. Armstrong, R. Allerton, D. Landers, H. Nicholas, L. McLellan, A. Lim, F. Mouliere, O. E. Pardo, V. Ferguson, M. J. Seckl
NATURE COMMUNICATIONS
(2023)
Editorial Material
Oncology
A. M. Kirby, J. S. Haviland, M. Mackenzie, H. Fleming, C. Anandadas, S. Wickers, E. Miles, N. Iles, J. M. Bliss, C. E. Coles, PARABLE Trial Management Grp
Article
Oncology
Paolo Nuciforo, John Townend, Martine J. Piccart, Shona Fielding, Panagiota Gkolfi, Sarra El-Abed, Evandro de Azambuja, Gustavo Werutsky, Judith Bliss, Volker Moebus, Marco Colleoni, Alvaro Moreno Aspitia, Henry Gomez, Andrea Gombos, Maria A. Coccia-Portugal, Ling-Ming Tseng, Georg Kunz, Guillermo Lerzo, Joohyuk Sohn, Vladimir Semiglazov, Cristina Saura, Judith Kroep, Antonella Ferro, David Cameron, Richard Gelber, Jens Huober, Serena Di Cosimo
Summary: Dual anti-HER2-targeted therapy combined with chemotherapy significantly improves the rate of pathological complete response (pCR) in breast cancer patients. However, limited data exist on the long-term impact of the increased pCR on survival.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Nicholas Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Hiroji Iwata, Wolfgang Janni, Cynthia X. Ma, Erica L. Mayer, Yeon Hee Park, Steven Fox, Xiaochun Liu, Sasha McClain, Francois-Clement Bidard
Summary: The purpose of this study is to test the effectiveness of a drug called Camizestrant in the treatment of breast cancer patients with estrogen receptor mutations. The study will monitor blood samples to observe if patients develop these mutations and evaluate whether switching to Camizestrant prolongs the time before cancer progresses and improves overall survival.
Article
Oncology
Holly Tovey, Orsolya Sipos, Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, Maggie Chon U. Cheang
Summary: This study explored the predictive ability of DNA damage response (DDR) and immune markers in the treatment response of triple-negative breast cancer. High immune features predict response to docetaxel, while high DDR signature scores predict response to carboplatin. Patients can be divided into different subgroups based on their treatment sensitivity. Caution is needed when using transcriptional signatures derived from primary tumors to guide treatment.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Galina Velikova, James P. Morden, Joanne S. Haviland, Charlotte Emery, Peter Barrett-Lee, Helena Earl, David Bloomfield, Adrian Murray Brunt, Peter Canney, Robert Coleman, Mark Verrill, Andrew Wardley, Gianfilippo Bertelli, Paul Ellis, Rob Stein, Judith M. Bliss, David Cameron
Summary: The study investigated the efficacy and toxicity of accelerated epirubicin and capecitabine in adjuvant chemotherapy for breast cancer. Results showed no benefit for accelerated epirubicin and capecitabine was non-inferior to CMF with less toxicity. The study also assessed the effect of chemotherapy on psychological distress, physical symptoms, and functional domains.
Review
Oncology
Giuseppe Curigliano, Rebecca Dent, Antonio Llombart-Cussac, Mark Pegram, Lajos Pusztai, Nicholas Turner, Giuseppe Viale
Summary: Risk stratification is crucial for early breast cancer diagnosis and treatment decisions. Various tools combining clinicopathological and molecular information can estimate the risk of recurrence and assess the potential benefits of different adjuvant treatments. While these tools provide similar prognostic accuracy at the population level, they may yield different risk predictions for individual patients.
Article
Oncology
Nicholas C. Turner, A. Douglas Laird, Melinda L. Telli, Hope S. Rugo, Audrey Mailliez, Johannes Ettl, Eva-Maria Grischke, Lida A. Mina, Judith Balmana, Peter A. Fasching, Sara A. Hurvitz, Julia F. Hopkins, Lee A. Albacker, Jijumon Chelliserry, Ying Chen, Umberto Conte, Andrew M. Wardley, Mark E. Robson
Summary: These analyses investigate the impact of homologous recombination repair gene mutations, including BRCA1/2 mutations and homologous recombination deficiency (HRD), on the efficacy of the PARP inhibitor talazoparib in the ABRAZO trial. The study finds that BRCA mutations and HRD have a significant effect on the efficacy of talazoparib in germline BRCA1/2-mutation carriers. The presence of BRCA1/2 mutations and loss of heterozygosity at BRCA locus indicate HRD. Non-BRCA tumor mutations, such as TP53 and PIK3CA, are also associated with specific BRCA mutations.
Meeting Abstract
Oncology
Eugene F. Schuster, Elena Lopez-Knowles, Anastasia Alataki, Lila Zabaglo, Elizabeth Folkerd, David Evans, Kally Sidhu, Holly Tovey, Perry Maxwell, Nicholas Turner, Stephen Johnston, Manuel Salto-Tellez, Maggie Chon U. Cheang, John Robertson, Ian Smith, Judith Bliss, Mitch Dowsett
Meeting Abstract
Oncology
Xixuan Zhu, Hui Xiao, Elena Lopez-Knowles, Milana A. Bergamino Sirven, Anastasia Alataki, Perry Maxwell, Holly Tovey, Lucy Kilburn, Chris Holcombe, Anthony Skene, Ian Smith, John Robertson, Katherine A. Hoadley, Roberto Salgado, Judith Bliss, Nicholas Turner, Manuel Salto-Tellez, Gene Schuster, Mitch Dowsett, Maggie Chon U. Cheang
Meeting Abstract
Oncology
Maggie Chon U. Cheang, Monisha Dewan, Lucy Kilburn, Gabriele Morani, Lila Zabaglo, Kally Sidhu, Holly Tovey, Xixuan Zhu, Chris Holcombe, Anthony Skene, Ian Smith, John Robertson, Alistair Ring, Nicholas Turner, Judith Bliss, Mitch Dowsett
Meeting Abstract
Oncology
Maria Coakley, Prithika Sritharan, Guillermo Villacampa, Claire Swift, Kathryn Dunne, Lucy Kilburn, Katie Goddard, Patricia Rojas, Andy Joad, Warren Emmett, Charlene Knape, Karen Howarth, Peter S. Hall, Catherine Harper-Wynne, Tamas Hickish, Iain Macpherson, Alicia F. Okines, Andrew M. Wardley, Duncan Wheatley, Simon Waters, Rosalind Cutts, Isaac Garcia-Murillas, Judith Bliss, Nicholas Turner
Article
Oncology
Judith M. Bliss, Holly Tovey, Abigail Evans, Chris Holcombe, Kieran Horgan, Elizabeth Mallon, Raghavan Vidya, Anthony Skene, Andrew Dodson, Margaret Hills, Simone Detre, Lila Zabaglo, Jane Banerji, Lucy P. Kilburn, James P. Morden, John F. R. Robertson, Ian Smith, Mitch Dowsett
Summary: Ki67(baseline) is an important prognostic factor in primary ER+ breast cancer, and the change in Ki67 after 2 weeks of treatment and residual Ki67 are associated with clinical benefit and recurrence-free survival. This study aimed to define the association between Ki67(baseline), increment Ki67(2week) after AI exposure, and Ki67(2week) with key prognostic and biologic factors using data from the POETIC study.
BREAST CANCER RESEARCH
(2023)
Article
Ethics
Dhrusti Patel, Lucy Kilburn, Lisa Fox, Emma Hall, Judith Bliss, Rebecca Lewis
Summary: Clinical trials should aim to be inclusive and reflect the population they are targeting. An audit of oncology trials conducted by ICR-CTSU revealed areas for improvement, such as reducing the use of gendered language and improving the readability of patient information. The collection of socio-economic factors needs to be standardized to adequately monitor under-served groups identified by NIHR.
BMC MEDICAL ETHICS
(2023)